Please upgrade your browser.
I was able to look at the following very interesting therapeutics which are novel treatments that primarily target tumor escape pathways.
Despite the development of novel targeted therapies, metastatic renal cell carcinoma (mRCC) remains an incurable disease. The known responsiveness of mRCC to immunotherapy and the molecular aberrations characteristic of this disease make it an attractive malignancy for treatment with oncolytic viruses (OVs), as these agents are capable of usurping common oncogenic signaling pathways and generating anti-tumor immune responses.
Researchers have discovered a new and exciting cancer treatment that uses the bodys own immune system to help fight the disease.
A list of abstracts from the 2012 ASCO meeting that mention kidney cancer. Do your own research. Become an empowered patient.
Bayer is testing regorafenib against a number of tumor types including kidney cancer.
Martin Voss, M.D., receives KCA/CCF Young Investigator Award at world's largest oncology meeting in Chicago.
Bristol-Myers Squibb Company (BMY) today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).
The gorjana Kidney Cancer Association Necklace has been designed especially for The Kidney Cancer Association. 50% of proceeds are donated to The Kidney Cancer Association to help individuals affected by kidney cancer.
While we expected patients would prefer one drug over the other, due to the known side effects, we didnt expect this great a preference, said the studys lead author, Bernard J. Escudier, M.D.
Recorded live at M. D. Anderson Cancer Center, Houston, Texas, these videos feature world-renown experts in the treatment of renal cancers.
|Powered by NeonCRM|